4/16
10:55 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
4/15
04:23 pm
ewtx
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) [Yahoo! Finance]
4/15
04:05 pm
ewtx
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Low
Report
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
3/28
08:09 am
ewtx
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session [Yahoo! Finance]
3/28
08:00 am
ewtx
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Low
Report
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
3/27
08:00 am
ewtx
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Low
Report
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
3/7
08:02 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $48.00 price target on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $48.00 price target on the stock.
3/5
08:23 am
ewtx
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 [Yahoo! Finance]
Neutral
Report
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 [Yahoo! Finance]
3/5
08:00 am
ewtx
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
Low
Report
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
2/28
08:20 am
ewtx
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference [Yahoo! Finance]
Low
Report
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference [Yahoo! Finance]
2/28
08:00 am
ewtx
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
Low
Report
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
2/22
08:23 am
ewtx
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
2/22
08:00 am
ewtx
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Medium
Report
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2/18
10:16 am
ewtx
Edgewise Therapeutics: Behind The Massive Rally [Seeking Alpha]
Low
Report
Edgewise Therapeutics: Behind The Massive Rally [Seeking Alpha]
2/13
08:38 am
ewtx
Krystal Biotech, Candel, Edgewise gain after FDA fast track tags [Seeking Alpha]
Neutral
Report
Krystal Biotech, Candel, Edgewise gain after FDA fast track tags [Seeking Alpha]
2/13
08:10 am
ewtx
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) [Yahoo! Finance]
Medium
Report
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) [Yahoo! Finance]
2/13
08:00 am
ewtx
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Low
Report
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
1/25
10:14 pm
ewtx
Edgewise Therapeutics Inc CFO R Carruthers Sells 90,000 Shares [Yahoo! Finance]
Medium
Report
Edgewise Therapeutics Inc CFO R Carruthers Sells 90,000 Shares [Yahoo! Finance]
1/24
11:59 am
ewtx
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet [Yahoo! Finance]
1/22
03:24 pm
ewtx
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock [Yahoo! Finance]
Medium
Report
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock [Yahoo! Finance]